Abstract

Introduction

For those with heavily treatment experienced (HTE) HIV-1 and virologic failure, therapeutic options are limited. A variety of barriers such as drug resistance, side effects, past intolerance, and administration inability contribute to the need for novel drug classes in this population.

Areas Covered

Herein, we review the pharmacology, clinical efficacy, and safety profile of fostemsavir, a first in its class attachment inhibitor recently FDA approved for use.

Expert Opinion

Fostemsavir is a well tolerated oral medication with relatively few drug-drug interactions. Clinical trial data demonstrates virologic and notable immunologic response in conjunction with optimal background therapy in HTE persons living with HIV. Fostemsavir exhibits no cross resistance with other ARV classes and thus is an important advancement for patients harboring drug resistant HIV. Further study will be needed to determine outstanding clinical questions such as the role of drug resistance testing and fostemsavir use outside of the HTE population.

中文翻译：

---

Fostemsavir用于治疗HIV

摘要

介绍

对于那些经历过大量治疗（HTE）HIV-1和病毒学衰竭的人，治疗选择有限。各种障碍，例如耐药性，副作用，过去的不耐受性和给药失能，导致对该人群中新型药物的需求。

覆盖区域

本文中，我们回顾了fostemsavir的药理学，临床疗效和安全性，fostemsavir是美国食品及药物管理局最近批准使用的同类抑制剂中的第一个。

专家意见

Fostemsavir是一种耐受性良好的口服药物，药物与药物之间的相互作用相对较少。临床试验数据表明，在HIV感染HTE患者中，病毒学和显着的免疫学反应与最佳背景治疗相结合。Fostemsavir与其他抗逆转录病毒药物没有交叉耐药性，因此对于携带抗药性HIV的患者而言是重要的进步。需要进行进一步的研究来确定悬而未决的临床问题，例如耐药性测试的作用以及在HTE人群以外使用fostemsavir的作用。